Point of Care Diagnostic test for Molecular Subtyping of Breast Cancer (PoCBreCa Study)

乳腺癌分子分型的护理点诊断测试（PoCBreCa 研究）

基本信息

批准号：
10348749
负责人：
Clement Adebayo Adebamowo
金额：
$ 17.67万
依托单位：
UNIVERSITY OF MARYLAND BALTIMORE
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-02-10 至 2025-01-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10348749
关键词：
Address African Area Baltimore Bioethics Biological Assay Biological Markers Breast Cancer Patient Breast Cancer Prevention Breast Cancer Treatment Cellular Phone Chemistry Clinical Research Conflict (Psychology)Continuity of Patient Care Country Diagnosis Diagnostic Reagent Kits Disease Epidemiologic Factors Epidemiology Epigenetic Process Evaluation Feasibility Studies Funding Genetic Genetic Variation Genomics Gold Hormone Receptor Human Resources Immunohistochemistry In Vitro Incidence Infrastructure Investigation Investments Knowledge Laboratories Logistics Malignant Neoplasms Mammary Neoplasms Maryland Methodology Methods Miniaturization Molecular Diagnosis Molecular Diagnostic Testing Molecular Epidemiology Nanotechnology New York Nigeria Outcome Pattern Phase Prognosis Research Research Personnel Resources Risk Sampling Standardization System Technology Tissue Microarray Tissues Training Training and Infrastructure United States Universities Validation Woman Work anticancer research base cancer clinical trial chemotherapy cost cost effective empowered epidemiology study epigenetic variation hormone therapy improved innovation low and middle-income countries malignant breast neoplasm medical schools molecular subtypes new technology novel novel strategies patient oriented research photonics pilot test point of care point-of-care diagnostics pre-clinical precision medicine predicting response prognostication receptor response sample archive side effect targeted treatment treatment research treatment response trend

项目摘要

Point of Care Diagnostic test for Molecular Subtyping of Breast Cancer (PoCBreCa) Study Project Summary The incidence of breast cancer in low and middle-income countries (LMIC) is rising rapidly. Despite this, very little is known about the epidemiology of molecular subtypes of breast cancer in these countries because of lack of facilities, resources and personnel for immunohistochemistry (IHC), the current gold standard for molecular subtyping of breast cancer. Innovative strategies that combine nanotechnology, photonics, miniaturization and cell phone networks to develop new technologies and kits can overcome these limitations and increase availability of molecular subtyping of breast cancer in LMIC. Increased availability of molecular subtyping will enable epidemiological research into the determinants and secular trend in the incidence of molecular subtypes of breast cancer in LMIC where previous studies have yielded conflicting results. It will also empower clinicians in their choice of breast cancer treatment, prediction of response and prognosis. The kits that we propose to develop in this project will generate quantitative results which will open new research and treatment opportunities for precision medicine based on quantitative levels of hormone receptors, its determinants and associations with germline and somatic, genetic and epigenetic variations. In this project, researchers at University of Maryland School of Medicine, Baltimore and Cornell University in the United States, and Center for Bioethics and Research, and the University of Ibadan in Nigeria work together to develop and pilot-test a point of care diagnostic kit for molecular subtyping of breast tumors and compare it to IHC in order to overcome current challenges and open new opportunities for breast cancer research.

乳腺癌分子亚型（POCBRECA）研究的护理点诊断测试项目摘要低收入和中等收入国家（LMIC）的乳腺癌发生率正在迅速上升。尽管如此，关于这些国家的乳腺癌分子亚型的流行病学知之甚少缺乏免疫组织化学的设施，资源和人员乳腺癌的分子亚型。结合纳米技术，光子学的创新策略，小型化和手机网络开发新技术和套件可以克服这些限制并增加LMIC中乳腺癌分子亚型的可用性。分子亚型的可用性提高将使流行病学研究能够对决定因素 LMIC中乳腺癌分子亚型发生率的世俗趋势和先前研究的发病率产生矛盾的结果。它还将使临床医生选择乳腺癌治疗，预测反应和预后。我们建议在该项目中开发的套件将产生定量结果这将根据定量水平的定量水平为精确医学开放新的研究和治疗机会激素受体，其决定因素以及与种系，体细胞，遗传和表观遗传学的关联变化。在这个项目中，巴尔的摩大学医学院和康奈尔大学的研究人员在美国，生物伦理学与研究中心以及尼日利亚伊巴丹大学的工作共同开发和试点测试乳腺肿瘤分子亚型的护理诊断套件和将其与IHC进行比较，以克服当前的挑战并为乳腺癌开放新的机会研究。